

Theodore S Nowicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4222807/publications.pdf>

Version: 2024-02-01

17
papers

1,168
citations

840119

11
h-index

940134

16
g-index

19
all docs

19
docs citations

19
times ranked

3084
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy. , 2022, 10, e004190.		5
2	Multiplexed imaging reveals an IFN- β -driven inflammatory state in nivolumab-associated gastritis. Cell Reports Medicine, 2021, 2, 100419.	3.3	9
3	PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer, 2020, 1, 46-58.	5.7	85
4	Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. Cancer Discovery, 2020, 10, 1645-1653.	7.7	11
5	A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clinical Cancer Research, 2019, 25, 2096-2108.	3.2	69
6	Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. Journal of Immunotherapy, 2018, 41, 248-259.	1.2	3
7	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	5.1	486
8	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 47-53.	1.0	287
9	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunology Research, 2017, 5, 118-126.	1.6	56
10	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatric Research, 2016, 79, 371-377.	1.1	12
11	Acquired Thrombotic Thrombocytopenic Purpura in Children: A Single Institution Experience. Indian Journal of Pediatrics, 2013, 80, 570-575.	0.3	6
12	Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction. Journal of Cellular Biochemistry, 2012, 113, 1998-2008.	1.2	41
13	BRAFV600E is associated with increased uPA levels in papillary thyroid cancer. Laryngoscope, 2011, 121, S273.	1.1	0
14	The Urokinase Plasminogen Activator System in Metastatic Papillary Thyroid Carcinoma: A Potential Therapeutic Target. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3062-3064.	1.8	2
15	Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle, 2011, 10, 100-107.	1.3	60
16	Rituximab Therapy to Prevent Relapse in Chronic Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Child. Pediatric Hematology and Oncology, 2011, 28, 167-172.	0.3	14
17	Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope, 2010, 120, 1383-1390.	1.1	20